Project Grant HT94252310739
Award Date 9/1/23
Completion Date 8/31/26
Dollars Obligated $1.2M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06511, USA
Similar Awards
- This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
- The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
- The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
- The Department of Defense's Defense Health Agency awarded a $558,832 Project Grant to Tufts University School of Medicine under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2024. This grant will support research focused on "Targeting Differentiation Epitope in CD11b of Tumor-Associated Inflammatory Monocytes: A Novel Adjuvant Dendritic Cell Therapy Approach for Mucosal Melanoma." The research aims to develop an innovative dendritic cell-based...
- Federal Grant Award Summary Yale University received a $1.3 million Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025 through June 30, 2029. The award supports the development of GUAR-T as a novel class of universal cellular immunotherapies for ovarian cancer. This research initiative represents a hypothesis-driven translational effort aimed at advancing cancer immunotherapy to address critical...
- The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...
- Federal Grant Award Summary Yale University received a $705,038 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2025 through June 30, 2029. The award supports the development of GUAR-T as a novel class of universal cellular immunotherapies for ovarian cancer treatment. This research initiative represents a translational effort to advance innovative immunotherapeutic approaches that address critical...
- The U.S. Defense Health Agency awarded Yale University a $912,487 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on the role of Polycomb Repressive Complex 1 in the progression of uveal melanoma. The 3-year research project, starting on September 15, 2023 and ending on September 14, 2026, aims to advance the understanding of this specific protein complex's involvement in the development and spread of a rare form...
- Federal Project Grant Award Summary Yale University received a $1,009,054 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2029. The award supports research focused on the discovery and therapeutic targeting of endogenous retroviruses in clear cell renal cell carcinoma. This biomedical research initiative addresses cancer treatment through investigation of endogenous...